CXCR4 and pulmonary fibrosis: Targeting CXCR4 as a therapeutic strategy in humans is appealing because this approach has been effective in several murine models of pulmonary fibrosis (17, 19, 26, 27), albeit with the usual caveats regarding the dissimilarities between mouse models and human pulmonary fibrosis.